|
|
LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. NYSE:BHCTSX:BHC and its gastroenterology GI business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis UC. The data will be presented at Digestive Disease Week DDW 2024 during the IMIBD Late Breakers and Innovations in... Lire le communiqué |
|
| |
|
| |
|
|
LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. NYSE:BHCTSX:BHC today announced the results of its 2024 annual meeting of shareholders.Annual Meeting ResultsThe 10 directors nominated at the Companys 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out... Lire le communiqué |
|
| |
|
| |
|
|
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. NYSE:BHCTSX:BHC and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc.With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel... Lire le communiqué |
|
| |
|
| |
|
|
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic Encephalopathy is caused by cirrhosis of the liverAs complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with their healthcare providers to find the right management plan for them LAVAL,... Lire le communiqué |
|
| |
|
| |
|
|
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYearoveryear revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. nonGAAP1 of $665 Million, up 13%... Lire le communiqué |
|
| |
|
| |
|
|
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. NYSE:NHCTSX:BHC will release firstquarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website... Lire le communiqué |
|
| |
|
| |
|
|
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. NYSE:BHCTSX:BHC, and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that... Lire le communiqué |
|
| |
|
| |
